tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CNTX Stock Latest News

Context Therapeutics Granted Nasdaq Extension for Compliance
Company AnnouncementsContext Therapeutics Granted Nasdaq Extension for Compliance
6d ago
8K
CNTX
Context Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Context Therapeutics Reports Q2 2025 Financial Results
17d ago
CNTX
Context Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
PremiumThe Fly
Context Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
1M ago
CNTX
Context Therapeutics reports Q2 EPS (9c), consensus (5c)
PremiumThe Fly
Context Therapeutics reports Q2 EPS (9c), consensus (5c)
1M ago
CNTX
Context Therapeutics price target lowered to $4 from $4.50 at Piper Sandler
PremiumThe Fly
Context Therapeutics price target lowered to $4 from $4.50 at Piper Sandler
2M ago
CNTX
Context Therapeutics Approves Reverse Stock Split Amendment
PremiumCompany AnnouncementsContext Therapeutics Approves Reverse Stock Split Amendment
3M ago
8K
CNTX
Context Therapeutics Highlights T Cell Engager Advancements
Premium
Company Announcements
Context Therapeutics Highlights T Cell Engager Advancements
3M ago
8K
CNTX
Context Therapeutics appoints Chagin as Chief Medical Officer
Premium
The Fly
Context Therapeutics appoints Chagin as Chief Medical Officer
3M ago
CNTX
Promising Progress in Context Therapeutics’ Cancer Treatment Advances: Buy Rating Affirmed
PremiumRatings
Promising Progress in Context Therapeutics’ Cancer Treatment Advances: Buy Rating Affirmed
4M ago
CNTX
Optimistic Buy Rating on Context Therapeutics Amid Promising Program Developments and Undervaluation
PremiumRatings
Optimistic Buy Rating on Context Therapeutics Amid Promising Program Developments and Undervaluation
4M ago
CNTX
Context Therapeutics CMO Claudio Dansky Ullmann to depart
PremiumThe Fly
Context Therapeutics CMO Claudio Dansky Ullmann to depart
4M ago
CNTX
Innovative Bispecific Antibody CT-95 Drives Buy Rating for Context Therapeutics
PremiumRatings
Innovative Bispecific Antibody CT-95 Drives Buy Rating for Context Therapeutics
4M ago
CNTX
Context Therapeutics presents preclinical data on CT-95
PremiumThe FlyContext Therapeutics presents preclinical data on CT-95
4M ago
CNTX
Context Therapeutics initiated with an Outperform at William Blair
Premium
The Fly
Context Therapeutics initiated with an Outperform at William Blair
5M ago
CNTX
Promising Outlook for Context Therapeutics: Buy Rating Backed by Innovative T-Cell Engagers and Strategic Pipeline Expansion
Premium
Ratings
Promising Outlook for Context Therapeutics: Buy Rating Backed by Innovative T-Cell Engagers and Strategic Pipeline Expansion
5M ago
CNTX
Context Therapeutics Begins Phase 1 Trial for CT-95
PremiumCompany Announcements
Context Therapeutics Begins Phase 1 Trial for CT-95
5M ago
8K
CNTX
Context Therapeutics doses first patient in Phase 1 trial of CT-95
PremiumThe Fly
Context Therapeutics doses first patient in Phase 1 trial of CT-95
5M ago
CNTX
Context Therapeutics: 2024 Financial and Strategic Highlights
PremiumCompany Announcements
Context Therapeutics: 2024 Financial and Strategic Highlights
5M ago
CNTX
Buy Rating Affirmed for Context Therapeutics Amid Strategic Advancements and Strong Financial Position
PremiumRatings
Buy Rating Affirmed for Context Therapeutics Amid Strategic Advancements and Strong Financial Position
6M ago
CNTX
Strategic Advancements and Financial Health Propel Context Therapeutics to a ‘Buy’ Rating
PremiumRatingsStrategic Advancements and Financial Health Propel Context Therapeutics to a ‘Buy’ Rating
6M ago
CNTX
Promising Clinical Trials and Strategic Pipeline Position Context Therapeutics for Success: A Buy Rating Justified
Premium
Ratings
Promising Clinical Trials and Strategic Pipeline Position Context Therapeutics for Success: A Buy Rating Justified
6M ago
CNTX
Context Therapeutics Advances CTIM-76 in Clinical Pipeline
Premium
Company Announcements
Context Therapeutics Advances CTIM-76 in Clinical Pipeline
8M ago
8K
CNTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >